Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology and CVMD


Identical twins share the same genetic make-up, yet due to lifestyle choices not always the same development of chronic diseases such as type 2 diabetes (T2D). Researchers have investigated the molecular mechanisms that induce T2D via an identical twin study, with the aim to better understand why one twin develops the disease while the other remains healthy.

Read more

Immunotherapy as an oncology treatment paradigm really came of age in 2014, with the first FDA approvals of anti-PD-1/PD-L1 therapies in advanced melanoma. Developments in the field look like they are not slowing down in 2015, with the race on for approval in the much larger lung cancer patient population.

Read more

The US FDA approved 41 novel new medicines in 2014, the highest number of approvals for 18 years. The list covered a wide variety of disease indications and included both interesting anticancer and antidiabetic agents, and notably 15 orphan drugs. We review the big hitters that made the list, and why some pricey agents are likely to reignite payer and public debate.

Read more

Darwin’s theory of natural selection was published in 1859, explaining how nature selects certain advantageous physical attributes (or phenotypes) to pass on to their offspring, so that they can better survive in their environment. Now over 150 years later, the theory is becoming a talking point in oncology, with natural selection within tumors helping to drive resistance mechanisms in cancer.

Read more